Astria Therapeutics Quote - ATXS

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

7.50

Bid

7.30

Ask

7.74

Volume

237,439

7.45 Day's Range 7.90

6.955 52 Week Range 16.90

Market Cap

423.257M

Previous Close

7.75

Open

7.85

Last Trade

7.68

Last Trade Time

Financial Volume

US$ 1,836,388

VWAP

7.7341

Average Volume (3m)

316,254

Shares Outstanding

56,434,219

Dividend Yield

PE Ratio

-6.61

Earnings Per Share (EPS)

-1.29

Revenue

Net Profit

-72.89M

Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for... Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.astriatx.com

Headquarters

Wilmington, Delaware, USA

Founded

Astria Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ATXS. The last closing price for Astria Therapeutics was US$7.75. Over the last year, Astria Therapeutics shares have traded in a share price range of US$ 6.955 to US$ 16.90.

Astria Therapeutics currently has 56,434,219 shares outstanding. The market capitalization of Astria Therapeutics is US$437.37 million. Astria Therapeutics has a price to earnings ratio (PE ratio) of -6.61.

Form 8-K - Current report

Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE

-- Single Pivotal Trial Designed to Demonstrate Efficacy and Safety of Every 3- and Every 6-Month Administration in a 6-Month Treatment Period -- -- Pioneering Patient-Centric Dosing Flexibility...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 58,650...

Form 8-K - Current report

Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE

-- Navenibart Demonstrated 6 Months of HAE Attack Prevention with 1 or 2 Doses -- -- 90-95% Mean Monthly Attack Rate Reduction Supporting Chronic Dosing 2 or 4 Times Per Year -- -- 67...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.7	-8.53658536585	8.2	8.2	7.16	448258	7.55170948	CS
4	-1.85	-19.7860962567	9.35	9.81	7.16	369119	8.58603973	CS
12	-4.2	-35.8974358974	11.7	12.515	7.16	316254	9.68370628	CS
26	-4.12	-35.4561101549	11.62	12.92	7.16	327221	10.65685114	CS
52	0.2	2.7397260274	7.3	16.9	6.955	564993	11.70856234	CS
156	2.87	61.9870410367	4.63	16.9	2.36	320377	10.4547506	CS
260	-1.03	-12.0750293083	8.53	16.9	2.36	292631	10.38475357	CS

ATXS - Frequently Asked Questions (FAQ)

What is the current Astria Therapeutics share price?

The current share price of Astria Therapeutics is US$ 7.50

How many Astria Therapeutics shares are in issue?

Astria Therapeutics has 56,434,219 shares in issue

What is the market cap of Astria Therapeutics?

The market capitalisation of Astria Therapeutics is USD 437.37M

What is the 1 year trading range for Astria Therapeutics share price?

Astria Therapeutics has traded in the range of US$ 6.955 to US$ 16.90 during the past year

What is the PE ratio of Astria Therapeutics?

The price to earnings ratio of Astria Therapeutics is -6.61

What is the reporting currency for Astria Therapeutics?

Astria Therapeutics reports financial results in USD

What is the latest annual profit for Astria Therapeutics?

The latest annual profit of Astria Therapeutics is USD -72.89M

What is the registered address of Astria Therapeutics?

The registered address for Astria Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801

What is the Astria Therapeutics website address?

The website address for Astria Therapeutics is www.astriatx.com

Which industry sector does Astria Therapeutics operate in?

Astria Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
BTCTBTC Digital Ltd	US$ 8.2697 (73.73%)	61.45M
BDMDBaird Medical Investment Holdings Ltd	US$ 8.80 (62.36%)	18.63M
CRKNCrown Electrokinetics Corporation	US$ 0.1235 (54.96%)	764.86M
NUKKNukkleus Inc	US$ 29.97 (45.98%)	19.09M
GSITGSI Technology	US$ 3.97 (44.36%)	87.7M
DOGZDogness International Corporation	US$ 18.23 (-58.77%)	740.45k
ORKTOrangeKloud Technology Inc	US$ 3.02 (-24.88%)	21.08M
PMAXPowell Max Ltd	US$ 0.6364 (-23.31%)	4.17M
LGCBLinkage Global Inc	US$ 0.2876 (-22.27%)	890.66k
YYAIConnexa Sports Technologies Inc	US$ 0.8299 (-20.20%)	602.48k
CRKNCrown Electrokinetics Corporation	US$ 0.1235 (54.96%)	764.86M
GCTKGlucoTrack Inc	US$ 0.0852 (15.45%)	465.22M
RIMEAlgorhythm Holdings Inc	US$ 0.0406 (-4.02%)	387.23M
TGLTreasure Global Inc	US$ 0.2459 (14.75%)	267.1M
NVDANVIDIA Corporation	US$ 137.71 (3.10%)	201.4M